Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel

Contraception

Volumn 63, Issue 1, 2001, Pages 1-11

  Knopp, Robert H ^a   Broyles, Frances E ^a   Cheung, Marian ^a,b   Moore, Katherine ^c   Marcovina, Santica ^b   Chandler, Wayne L ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c MADIGAN ARMY MEDICAL CENTER   (United States)

Author keywords

Carbohydrates; Desogestrel; Hemostasis; Levornogestrel; Lipids; Oral contraceptives; SHBG

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR 5; CARBOHYDRATE; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; ESTROGEN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GESTAGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEVONORGESTREL; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL CONTRACEPTIVE AGENT; PROTEIN S; SEX HORMONE BINDING GLOBULIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARBOHYDRATE METABOLISM; CONTROLLED STUDY; DRUG EFFECT; DRUG FORMULATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESPONSE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; METABOLIC REGULATION; NORMAL HUMAN; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; APOLIPOPROTEINS B; BLOOD COAGULATION; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CONTRACEPTIVES, ORAL; DESOGESTREL; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMANS; INSULIN; LEVONORGESTREL; LIPIDS; LIPOPROTEIN(A); SEX HORMONE-BINDING GLOBULIN; TRIGLYCERIDES;

EID: 0035068298     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(00)00196-7     Document Type: Article

References (62)

1. Some effects of oral contraceptives on serum-lipid and lipoprotein levels
2. Glucose and insulin alterations after one year of combination-type oral contraceptive treatment
3. Investigation of relation between use of oral contraceptives and thromboembolic disease
4. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: Relationships to estrogen and progestin potency
5. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol
6. The evolution of oral contraceptives. Maximizing efficacy, minimizing risks
7. Sex hormones and lipid interactions: Implications for cardiovascular disease in women
8. Estrogen replacement therapy for reduction of cardiovascular risk in women
9. Estrogen, female gender, and heart disease
10. Binding of progestagens to receptor proteins in MCF-7 cells
11. Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives
12. Evaluation of a new generation of oral contraceptives
13. A comparison of the potencies, and activities of progestogens used in contraceptives
14. Findings leading to discontinuation of the 2.5-mg day estrogen group
15. Risk of venous thromboembolism in users of hormone replacement therapy
16. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
17. Prospective study of exogenous hormones and risk of pulmonary embolism in women
18. Biological coagulation findings in third-generation oral contraceptives
19. Epidemiology of cardiovascular disease in women and the role of sex steroid hormone use
20. Coagulation effects of oral contraception
21. Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid
22. Comparative metabolic effects of oral contraceptive preparations containing different progestagens. Effects of desogestrel + ethinylestradiol on the haemostatic balance
23. Blood coagulation with a combination pill containing gestodene and ethinyl estradiol
24. Influence of modern low-dose oral contraceptives on hemostasis
25. Comparative studies of 30 micrograms ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis, and platelets
26. The northwest lipid research clinic fat intake scale: Validation and utility
27. A liquid-phase immunoradiometric assay (IRMA) for human sex hormone binding globulin (SHBG)
28. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol
29. Precipitation methods for quantification of lipoproteins
30. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material
31. The measurement of apolipoprotein A-I and A-II levels in men and women by immunoassay
32. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material
33. Lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in Caucasians and African Americans. The CARDIA study
34. Automated glucose methods: Evaluation of a glucose oxidase-peroxidase procedure
35. Immunoassay of insulin: Two antibody system: Plasma insulin levels of normal, subdiabetic and diabetic rats
36. Prothrombin times and clottable fibrinogen determination on an automated coagulation laboratory (ACL-810)
37. Comparison of activated partial thromboplastin reagents
38. Quantitative one-stage assays for factors V and X
39. Assay of antihemophilic A, B and C factors by one-stage cephalin system
40. Improved assay of antithrombin-III. Effects of certain additives on thrombin and on chromogenic peptide substrates
41. Rapid amidolytic assay of protein C in whole plasma using an activator from the venom of Agkistrodon contortrix
42. An abnormal plasma distribution of protein S occurs in functional protein S deficiency
43. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA
44. Measurement of tPA and tPA-PAI-1 complexes by ELISA, using monoclonal antibodies: Clinical relevance
45. Effects of physical conditioning on fibrinolytic variables and fibrinogen in young and old healthy adults
46. Comparison of the effects of triphasic oral contraceptives with desogestrel or levonorgestrel on apolipoprotein A-I-containing high-density lipoprotein particles
47. Lipid and lipoprotein changes in women taking low-dose, triphasic oral contraceptives: A controlled, comparative, 12-month clinical trial
48. Effects of low-dose multiphasic oral contraceptives over one year on total and LDL-C in comparison to preceding and succeeding normal menstrual cycles
49. The effect of triphasic oral contraceptives on plasma lipids and lipoproteins
50. Serum levels of 3-keto-desogestrel and SHBG during 12 cycles of treatment with 30 micrograms ethinylestradiol and 150 micrograms desogestrel
51. Carbohydrate metabolism during treatment with estrogen, progestogen, and low-dose oral contraceptives
52. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study
53. Menopause and risk factors for coronary heart disease
54. A randomized crossover comparison of two low-dose contraceptives: Effects on serum lipids, and lipoproteins
55. Effect on lipid metabolism of a biphasic desogestrel-containing oral contraceptive: Divergent changes in apolipoprotein B and E and transitory decrease in Lp(a) levels
56. Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanozolol
57. Lipoprotein (a) concentrations in postmenopausal women taking norethisterone
58. Estrogen replacement therapy and coagulation: Relationship to lipid and lipoprotein changes
59. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: A review
60. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: A cross-over study
61. Low-dose oral contraceptives and acquired resistance to activated protein C: A randomized cross-over study